Navigation Links
FTC Ends Investigation of CVS Caremark
Date:1/12/2012

WOONSOCKET, R.I., Jan. 12, 2012 /PRNewswire/ -- CVS Caremark Corporation (NYSE: CVS) announced today that the Federal Trade Commission (FTC) has concluded its investigation under the Federal Trade Commission Act into the company's business practices.  The investigation has resulted in CVS Caremark entering into a consent order that relates to certain business practices of a subsidiary of Longs Drug Stores Corporation, which took place prior to the acquisition of Longs by CVS Caremark in October 2008.  There were no allegations of antitrust law violations or anti-competitive behavior related to CVS Caremark's business practices or its products or service offerings.  In addition, the Company has received a formal letter from the FTC closing all other aspects of the investigation.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO )

Pursuant to the consent order, CVS Caremark will deposit $5 million into a fund that will be used to compensate consumers who purchased coverage for the 2008 plan year from a Medicare Part D Prescription Drug Plan sponsored by Rx America, a subsidiary of Longs.  The fund is being established as a result of Rx America inadvertently posting on a website maintained by the Centers for Medicare and Medicaid Services (CMS) inaccurate pricing information for certain generic drugs.  In addition, CVS Caremark agreed on a go forward basis to refrain from making any misrepresentations regarding drug pricing information relating to affiliate sponsored Medicare Part D plans. The consent order will be published in the Federal Register and is subject to comment for 30 days.

"CVS Caremark is pleased to have reached an agreement with the FTC that ends the investigation and enables us to continue our focus on offering unique, innovative products a
'/>"/>

SOURCE CVS Caremark
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
3. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
7. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
11. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... CAMBRIDGE, Mass., Sept. 21, 2011 IntelligentMDx (IMDx) announced today ... test for the Abbott FDA cleared m 2000 instrument. ... detects and distinguishes the vanA and vanB ... specimens from patients at risk for colonization or infection. Detection ...
... 21, 2011 Mylan Inc. (Nasdaq: MYL ... settlement and license agreement with Hoffman La Roche Inc. ... 500 mg, USP, known generically as Capecitabine Tablets. This ... the treatment of metastatic breast and colorectal cancers. ...
Cached Medicine Technology:IntelligentMDx (IMDx) Introduces a CE-Marked Automated Molecular Test for the Detection of Vancomycin Resistance Genes vanA and vanB Most Commonly Found in Vancomycin-Resistant Enterococci 2Mylan Announces XELODA® Settlement and License Agreement 2
(Date:4/24/2014)... will bring together national experts to discuss solutions ... inaugural Brain Health Summit, titled "The Human Brain: ... Dr. Sandra Bond Chapman, founder and chief director ... Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) and ... Early Learning, U.S. Department of Education. The day ...
(Date:4/24/2014)... End-of-life aspects, the corresponding terminology, and the relevance ... considered in publications on randomized controlled trials (RCTs). ... the German Institute for Quality and Efficiency in ... as final report. , Together with external experts, ... examples: glioblastoma, lung cancer, malignant melanoma, and pancreatic ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
(Date:4/24/2014)... An Oregon State University researcher has found a relationship ... symptoms of autism spectrum disorder in very young children. ... first to show a direct relationship between motor skills ... gross motor skills should be included in treatment plans ... assistant professor in OSU,s College of Public Health and ...
(Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... ... University Edwardsville School of Pharmacy has been awarded -- along with the Saint ... (NIH) grant to study ways of relieving chronic pain through new approaches in treating ... ...
... Kimberly-Clark Corporation (NYSE: KMB ) has joined forces ... performance of some of its product packaging. The new ... which benefit schools and communities nationwide. , Kimberly-Clark, ... health, hygiene, and well being, and TerraCycle are now ...
... Life ... , ... 2009 -- Life Care Centers of America recently named Michael Lops as its ... Care, succeeds Sharon Coleman in the position. His appointment is based on “his extensive experience ...
... , MONDAY, Nov. 2 (HealthDay News) -- Though someone ... lack basic knowledge about the potentially life-threatening disease, according ... , Diabetes is responsible for more deaths each year ... combined, but just 42 percent of those surveyed knew ...
... , ROCKVILLE, Md., Nov. 2 Vanda Pharmaceuticals Inc. (Vanda) ... development and commercialization of clinical-stage products for central nervous system ... quarter ended September 30, 2009. , Vanda reported ... of 2009, compared to $12.4 million for the second quarter ...
... , Preliminary evaluation after completion of ... endpoint has been met for patients with advanced-stage, ... Nov. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; ... company focused on endocrine therapy and oncology, today announced ...
Cached Medicine News:Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 2Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 3Health News:SIUE School of Pharmacy, SLU Pharmacology Receive $975K NIH Grant 4Health News:Kimberly-Clark & TerraCycle, Inc. Partner to Reduce Waste and Help Fund Schools and Non-Profits 2Health News:Kimberly-Clark & TerraCycle, Inc. Partner to Reduce Waste and Help Fund Schools and Non-Profits 3Health News:Lops named Life Care's New Chief Compliance Officer 2Health News:Americans Get Failing Grade on Diabetes Awareness 2Health News:Americans Get Failing Grade on Diabetes Awareness 3Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 2Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 3Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 4Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 5Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 6Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 7Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 8Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 9Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 10Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 11Health News:Vanda Pharmaceuticals Reports Third Quarter 2009 Results 12Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 2Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 3Health News:AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer 4
... for the detection and semi-quantitation of human ... (SLE), Western Equine Encephalitis (WEE), Eastern Equine ... group viruses. Each kit contains ten 8-well ... WEE, EEE, and CE in each well, ...
... immunofluorescent antibody ( RIFA:) test ... of human serum IgM antibodies ... (VCA). Each kit contains ten ... EBV VCA antigen, FITC IgM ...
... immunofluorescent antibody (IFA) test for the ... IgG antibodies to the detection and ... Epstein-Barr virus early antigens, both restricted ... contains ten 12-well slides, FITC conjugate, ...
CMF OL1000 Bone Growth Stimulators are portable, battery-powered medical devices indicated for use in the noninvasive treatment of an established nonunion fracture acquired secondary to trauma, exclu...
Medicine Products: